Alaunos Therapeutics | ZIOP


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Amgen 221.22 -0.66 -0.30% -10.22%
AstraZeneca 11,806.00 -26.00 -0.22% 14.51%
Baxter International 40.96 -0.69 -1.66% -43.57%
Biogen 299.79 -2.34 -0.77% 49.09%
Bioline Rx 1.60 0 0% 5.96%
Bristol-Myers Squibb 65.48 -0.50 -0.76% -14.05%
Corcept Therapeutics 23.56 0.33 1.42% 9.99%
Curis 0.84 0.002 0.20% -19.07%
Gilead Sciences 76.20 -1.52 -1.96% 22.15%
GlaxoSmithKline 1,392.20 0.80 0.06% -20.49%
Intercept Pharmaceuticals 11.31 0.12 1.07% -22.32%
Immunogen 15.15 -0.22 -1.43% 274.07%
Incyte Corp 61.71 -0.66 -1.06% -17.62%
Ionis Pharmaceuticals 43.33 1.07 2.53% 23.69%
J&J 158.18 -0.14 -0.09% -11.30%
Karyopharm Therapeutics 2.38 0.08 3.48% -61.43%
Merck & Co 110.01 -3.10 -2.74% 21.58%
Novartis 90.55 0.03 0.03% 5.56%
Pfizer 38.37 -0.28 -0.72% -28.89%
PTC Therapeutics 45.02 2.45 5.74% 58.67%
Regeneron Pharmaceuticals 748.14 -2.13 -0.28% 23.10%
Roche Holding 290.20 -1.95 -0.67% -9.16%
Sangamo BioSciences 1.26 0.10 8.62% -68.66%
TG Therapeutics 26.49 0.64 2.48% 527.73%
Verastem 11.55 -0.50 -4.15% 752.40%
Intrexon 1.30 -0.04 -2.99% -15.03%
Alaunos Therapeutics 0.47 0.01 2.11% -30.24%

Indexes Price Day Year
USND 13276 46.99 0.36% 9.04%
US2000 1855 48.69 2.69% -3.34%

Alaunos Therapeutics

Alaunos Therapeutics Inc traded at $0.47 this Tuesday June 6th, increasing $0.01 or 2.11 percent since the previous trading session. Looking back, over the last four weeks, Alaunos Therapeutics gained 20.72 percent. Over the last 12 months, its price fell by 30.24 percent. Looking ahead, we forecast Alaunos Therapeutics Inc to be priced at 0.49 by the end of this quarter and at 0.44 in one year, according to Trading Economics global macro models projections and analysts expectations.

Alaunos Therapeutics, Inc. is a clinical-stage oncology-focused cell therapy company. It is engaged in developing adoptive TCR engineered T-cell therapies (TCR-T), designed to treat multiple solid tumor types in large cancer patient populations. It is leveraging its cancer mutation hotspot TCR library and its non-viral Sleeping Beauty genetic engineering technology to design and manufacture patient-specific cell therapies that target neoantigens arising from common tumor-related mutations in oncogenic genes, including KRAS, TP53 and EGFR. Its TCR library consists of ten TCRs targeting six solid tumor indications, such as non-small cell lung, colorectal, endometrial, pancreatic, ovarian and bile duct cancers. Using its human neoantigen T cell Receptor discovery engine, it analyzes thousands of single T cells simultaneously using bioinformatics and next generation sequencing. Its pipeline in cell therapy for oncology consists of Library TCR-T cell therapy and mbIL-15 TCR-T cell therapy.